Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT06121557 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

PROCEDURE: Surgery for harvesting tumor-draining lymph nodes
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Tumor-draining lymph node-derived lymphocyte (LNL)
BIOLOGICAL: Interleukin-2
BIOLOGICAL: Camrelizumab
DRUG: Chemotherapeutic drug, ADC or PARP inhibitor

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University